BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $27,275.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 1,091 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the completion of the sale, the insider now directly owns 58,816 shares of the company’s stock, valued at $1,470,400. The trade was a 1.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $25.00 on Friday. The stock’s 50 day moving average price is $26.59 and its 200 day moving average price is $25.49. The firm has a market capitalization of $1.18 billion, a PE ratio of -23.58 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same period in the prior year, the company posted ($0.21) EPS. As a group, sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. grew its stake in shares of BioLife Solutions by 4.7% in the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after purchasing an additional 8,580 shares in the last quarter. Curi RMB Capital LLC grew its stake in shares of BioLife Solutions by 0.5% in the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after purchasing an additional 2,283 shares in the last quarter. Quest Partners LLC bought a new position in shares of BioLife Solutions in the third quarter worth $57,000. Intech Investment Management LLC bought a new position in shares of BioLife Solutions in the third quarter worth $255,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of BioLife Solutions by 3.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 319,959 shares of the medical equipment provider’s stock worth $8,012,000 after purchasing an additional 9,750 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. HC Wainwright raised their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.